Skip to main content

Table 2 Blood pressures, Blood biochemical parameters, Lipid and protein oxidative products, Sodium excretion rate, and HBMD in people with treated T2D before (baseline) and after treatment (24-week) within the Main (Experimental) and Control (Conventional) groups (M ± SEM)

From: Weight loss technology for people with treated type 2 diabetes: a randomized controlled trial

Variables Main group, n = 208 Control group, n = 64
Baseline 24-week Baseline 24-week
Systolic blood pressure (mmHg) 154.3 ± 1.22 120.4 ± 0.67** 150.4 ± 1.76 128.7 ± 2.17**
Diastolic blood pressure (mmHg) 98.7 ± 0.75 80.92 ± 0.63** 98.1 ± 0.98 93.2 ± 1.29*
Hemoglobin (g/L) 126.5 ± 0.68 138.9 ± 0.62** 127.1 ± 0.71 127.4 ± 0.72
ESR (mm/Hour) 23.4 ± 0.64 7.66 ± 0.26** 22.9 ± 0.70 24.8 ± 0.75*
Eosinophilia (%) 5.35 ± 0.21 1.82 ± 0.14** 5.29 ± 0.29 6.08 ± 0.30*
Glucose (mmol/L) 8.64 ± 0.19 4.50 ± 0.11** 8.58 ± 0.24 6.04 ± 0.21**
2-hour OGTT (mmol/L) 14.5 ± 0.28 6.7 ± 0.19** 14.1 ± 0.33 8.21 ± 0.42**
HbA1c (mmol/mol and %) 52.0 ± 0.68 (6.91 ± 0.09) 35.0 ± 0.52** (5.39 ± 0.08) 52.0 ± 1.13 (6.89 ± 0.15) 46.0 ± 1.15* (6.38 ± 0.16)
Cholesterol (mmol/L) 5.82 ± 0.07 4.54 ± 0.05** 5.77 ± 0.09 5.47 ± 0.11*
Triglyceride (g/L) 2.42 ± 0.08 0.81 ± 0.05** 2.21 ± 0.08 1.92 ± 0.12*
Total Fibrinogen (g/L) 4.52 ± 0.07 2.21 ± 0.06** 4.58 ± 0.09 4.05 ± 0.18*
MDA (μmol/L) 48.47 ± 0.68 33.48 ± 0.29** 46.99 ± 0.75 50.46 ± 0.79*
SOD (U/mg) 53.83 ± 0.54 77.71 ± 0.67** 52.91 ± 0.65 56.87 ± 0.97*
Catalase (U/g) 22.17 ± 0.42 26.44 ± 0.46** 23.81 ± 0.49 25.17 ± 0.68
AOPP (μmol/L) 266.8 ± 12.6 181.8 ± 7.8** 262.4 ± 13.6 295.6 ± 13.9*
Sodium in the urine (mmol/L) 164.1 ± 2.8 32.4 ± 1.9** 164.1 ± 2.8 182.4 ± 3.5**
Sodium in the blood (mmol/L) 134.4 ± 0.32 143.7 ± 0.38** 135.1 ± 0.35 134.1 ± 0.34*
HBMD (Units) 77.83 ± 1.86 93.2 ± 1.37** 78.78 ± 1.92 76.87 ± 1.88
  1. Abbreviations: ANADET analimentary detoxication, AOPP advanced oxidation protein products, ESR erythrocyte sedimentation rate, HBMD heel bone mineral density, M mean, MDA malondialdehyde, OGTT oral glucose tolerance test, SOD superoxide dismutase, SEM standard error of the mean, T2D type 2 diabetes
  2. *P-value of < 0.05, and
  3. **P < 0.0001 were set as significant between baseline and 24-week treatment within group comparison